cancers-logo

Journal Browser

Journal Browser

Outcomes in Glioblastoma Patients: From Diagnosis to Palliation: 2nd Edition

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: 15 October 2026 | Viewed by 999

Special Issue Editors


E-Mail Website
Guest Editor
Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy
Interests: functional neurosurgery; cerebrovascular disease; neuro-oncology
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Neurosurgery Unit, Department of Translational Medicine and for Romagna, University of Ferrara, Ferrara, Italy
Interests: neuro-oncology; pain treatment; functional neurosurgery; CSF physiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of a previous one on the topic of "Outcomes in Glioblastoma Patients: From Diagnosis to Palliation” (https://www.mdpi.com/journal/cancers/special_issues/UM166810A0).

One of the most challenging aspects in the treatment of high grade glioma (HGG) is the outcome assessment and the subsequent prognostic prevision. With the advancement of technical possibilities, it becomes fundamental to pursue a patient-tailored approach that takes into account a multitude of variables, including clinical, radiological, biomolecular and personal factors. This is particularly true for HGG patients that face the tremendous impact of such an aggressive tumor, as at each step of cure, a fundamental decision has to be made where every element is crucial. The most known example of a prognostic factor in HGG is the MGMT promoter methylation status and the response to alkylating agent chemotherapy, but many others are now under consideration in laboratory and clinical practice. From the first radiological evaluation to supportive end-of-life care, outcome assessment and prevision are of the utmost importance in HGG patient’s management to avoid both under or over treatments. This Special Issue will focus on the recent evidence on HGG’s Quoad vitam prognosis (prognostic radiological, clinical, biological, and genetical markers) and Quoad valetudinem prognosis (neurological and functional assessment of HGG patients, before and after therapy, including the psycho-social well-being of patients and caregivers).

Dr. Alba Scerrati
Dr. Giorgio Mantovani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • high-grade glioma
  • outcome assessment
  • prognostic factors
  • neuro-oncology
  • glioblastoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1185 KB  
Article
Multiple Primaries: Differences in Survival of Patients with Glioma with or Without Second Malignancies
by Matthias Demetz, Aleksandrs Krigers, Alexander Miller-Michlits, Adelheid Wöhrer, Claudius Thomé, Christian F. Freyschlag and Johannes Kerschbaumer
Cancers 2025, 17(21), 3584; https://doi.org/10.3390/cancers17213584 - 6 Nov 2025
Viewed by 752
Abstract
Background and Objectives: The biological behavior of gliomas is influenced by various factors including molecular features and treatment response. This study investigates the prognostic implications of a second tumor in patients with glioma at time of diagnosis. Given the increasing number of patients [...] Read more.
Background and Objectives: The biological behavior of gliomas is influenced by various factors including molecular features and treatment response. This study investigates the prognostic implications of a second tumor in patients with glioma at time of diagnosis. Given the increasing number of patients presenting with multiple primary malignancies due to improved cancer survival and diagnostic accuracy, understanding the influence of double tumor burden on glioma outcomes is of growing clinical relevance. Methods: We retrospectively analyzed adult patients with intracranial gliomas (WHO grade 2–4), who were surgically treated between 2015 and 2022 at our institution. Patients were categorized into two groups: glioma only and glioma plus additional solid malignancy. We compared progression-free survival (PFS) and overall survival (OS) using Kaplan–Meier and Cox regression analyses. Results: Among 426 glioma patients, 75 (17.6%) harbored a second non-brain tumor. Patients with multiple primaries showed significantly poorer OS (median 6 vs. 14 months, p = 0.002). No significant difference in PFS or OS was observed for patients in case the systemic tumor was in complete remission as compared to those with sole glioma. However, patients with progressive or stable systemic tumor had significantly worse outcomes regarding OS (p < 0.05). Conclusions: Our findings suggest that the presence of a second systemic malignancy is an independent prognostic factor for worse outcome. Further studies are mandated to elucidate genetic situations and refine therapeutic strategies for these patients. Full article
Show Figures

Figure 1

Back to TopTop